Key result
Tolterodine increases mean heart rate by ≥5 bpm more frequently than darifenacin or placebo.
Why the study?
Do antimuscarinic drugs (tolterodine and darifenacin) increase heart rate compared to placebo in healthy participants ≥50 years?
Population
162 healthy participants ≥50 years
Comparison
Tolterodine 4 mg/d or darifenacin 15 mg/d for 7… vs Placebo for 7 days
Design
RCT, randomized (3-way crossover), double-blind
Follow-up
7 days
Authors
Loading...
Darifenacin may be preferable to tolterodine to limit heart rate increases; confirms M3 selectivity reduces cardiac effects in older adults.
RCT (n=162)
Double-blind
3-way crossover
Do antimuscarinic drugs (tolterodine and darifenacin) increase heart rate compared to placebo in healthy participants ≥50 years?
p-value: p=0.0004 vs darifenacin; 0.0114 vs placebo
Nonselective antimuscarinics like tolterodine increase heart rate compared to highly selective M3 blockers like darifenacin, highlighting the importance of muscarinic receptor profiles when selecting overactive bladder treatments.
Olshansky et al. (2008) conducted an RCT in Healthy (n=162). Tolterodine and Darifenacin vs. Placebo was evaluated on Proportion of participants with an increase in mean heart rate per 24 hours of ≥5 beats per minute (p=0.0004 vs darifenacin; 0.0114 vs placebo). Tolterodine significantly increased the proportion of participants with a mean heart rate increase of ≥5 bpm compared to darifenacin (P=0.0004) and placebo (P=0.0114).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: